FibroBiologics Q1 EPS Forecast Increased by HC Wainwright

FibroBiologics Inc. (NASDAQ:FBLG) – Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of FibroBiologics in a research report issued to clients and investors on Thursday, February 26th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.07) per share for the quarter, up from their prior estimate of ($0.10). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.50) EPS and FY2029 earnings at ($0.65) EPS.

A number of other research analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. D. Boral Capital decreased their price objective on FibroBiologics from $15.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, FibroBiologics has a consensus rating of “Hold” and an average target price of $5.50.

FibroBiologics Stock Down 7.2%

Shares of FBLG opened at $0.39 on Monday. FibroBiologics has a twelve month low of $0.22 and a twelve month high of $1.53. The stock has a market capitalization of $26.31 million, a P/E ratio of -0.93 and a beta of -0.69. The company has a 50 day moving average of $0.29 and a 200-day moving average of $0.38.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.06.

Insider Buying and Selling at FibroBiologics

In related news, CFO Jason Davis acquired 70,000 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were purchased at an average cost of $0.41 per share, for a total transaction of $28,700.00. Following the completion of the acquisition, the chief financial officer directly owned 70,000 shares in the company, valued at approximately $28,700. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel Ruben A. Garcia purchased 140,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $0.34 per share, for a total transaction of $47,600.00. Following the purchase, the general counsel owned 140,000 shares in the company, valued at $47,600. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 250,000 shares of company stock valued at $89,500 in the last ninety days. Insiders own 13.00% of the company’s stock.

Hedge Funds Weigh In On FibroBiologics

Several institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC acquired a new stake in FibroBiologics in the 1st quarter worth about $29,000. XTX Topco Ltd raised its holdings in FibroBiologics by 160.0% in the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after acquiring an additional 28,276 shares in the last quarter. Ethos Financial Group LLC grew its holdings in shares of FibroBiologics by 100.0% during the 2nd quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock worth $30,000 after purchasing an additional 24,424 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of FibroBiologics in the second quarter worth $37,000. Finally, Marshall Wace LLP bought a new stake in FibroBiologics during the second quarter worth about $49,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.